| Literature DB >> 27885434 |
Yutong He1, Jing Jin1, LiQun Wang1, Yuejiao Hu2, Di Liang1, Huichai Yang3, Yueping Liu3, Baoen Shan4.
Abstract
MicroRNAs have been associated with prognosis in oesophageal cancer (EC), suggesting that miRNAs could play a role in guiding treatment decisions. The aim of this study was to evaluate the prognostic potential of miRNAs found to be associated with zinc deficiency in a geographical area with a high incidence of EC. miRNAs found to be associated with zinc deficiency were isolated from EC cell lines cultured with various Zn levels. The expression levels of the miRNAs were quantified using qRT-PCR. The potential prognostic value of the selected miRNAs was assessed in a cohort study of 88 patients from an area in China with a high incidence of EC. Correlations between miRNAs and patient characteristics were assessed using χ2 statistical tests or Fisher's exact test. A Cox proportional hazards model was used to assess the correlations between miRNAs and overall survival (OS). Forest plots were performed to evaluate the prognostic impact of the miRNAs examined in the present study in the Asian population. The expression levels of miR-21, miR-31, miR-93 and miR-375 were different when Zn levels were varied in EC cell lines, but only miR-21 and miR-375 were associated with patient characteristics and prognosis in patients with EC from an area of China with a high incidence of EC. The patients expressing high levels of miR-21 had poor OS (HR 2.15, 95% CI 1.16-3.97), whereas those with high levels of miR-375 had improved OS (HR 0.47, 95% CI 0.26-0.87).The patients with both a high level of miR-375 and a low level of miR-21 had significantly better outcomes. Forest plots based on an analysis of this Asian population indicated that a high level of miR-21 significantly predicted a shortened OS (HR 1.83, 95% CI 1.42-2.37), whereas a high level of miR-375 was significantly correlated with increased survival (HR 0.56, 95% CI 0.43-0.73). MiR-21 and miR-375 could be used as prognostic biomarkers in areas with a high incidence of EC, and combining these markers may results in a better effect.Entities:
Keywords: Oesophageal cancer; Prognostic; miR-21; miR-375
Mesh:
Substances:
Year: 2016 PMID: 27885434 PMCID: PMC5285435 DOI: 10.1007/s10585-016-9828-4
Source DB: PubMed Journal: Clin Exp Metastasis ISSN: 0262-0898 Impact factor: 5.150
Patient and tumor characteristics
| Cohort | Cases | % | Deaths | % |
|---|---|---|---|---|
| Gender | ||||
| Male | 69 | 78.4 | 38 | 55.1 |
| Female | 19 | 21.6 | 8 | 42.1 |
| Age | ||||
| <65 | 31 | 35.2 | 19 | 61.3 |
| ≥65 | 57 | 64.8 | 27 | 47.4 |
| Pathogenic sites | ||||
| Upper | 5 | 5.7 | 2 | 40.0 |
| Middle | 22 | 25.0 | 6 | 27.3 |
| Lower | 61 | 69.3 | 38 | 62.3 |
| Pathological type | ||||
| ESCC | 71 | 80.7 | 38 | 52.8 |
| Other | 17 | 19.3 | 8 | 47.1 |
| TNM stage | ||||
| I | 7 | 8.0 | 1 | 14.3 |
| II | 18 | 20.5 | 6 | 33.3 |
| III | 63 | 71.5 | 39 | 61.9 |
| Postoperative metastasis | ||||
| Yes | 38 | 66.7 | 22 | 57.9 |
| No | 19 | 33.3 | 7 | 36.8 |
Fig. 1a Expression levels of miRNAs in KYSE170 cells grown with and without Zn. The cell line without Zn was cultured in RPMI 1640 medium with 10% foetalbovine serum, and the cell line with Zn was cultured in RPMI 1640 medium with 10% FBS plus 50 µmol/L ZnSO4. b Expression levels of miRNAs in Eca109 cells grown with and without Zn. The cell line without Zn was cultured in RPMI 1640 medium with 10% foetalbovine serum, and the cell line with Zn was cultured in RPMI 1640 medium with 10% FBS plus 50 µmol/L ZnSO4
Association of the miR-21 and miR-375 with patient characteristics
| Factor | High miR-21 (n = 42) | Low miR-21 (n = 46) | χ2 |
| High miR-37 (n = 42) | Low miR-375 (n = 46) | χ2 |
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |||||
| Gender | 1.004 | 0.229 | 0.443 | 0.506 | ||||||||
| Male | 31 | 44.9 | 38 | 55.1 | 35 | 50.7 | 34 | 49.3 | ||||
| Female | 11 | 57.9 | 8 | 42.1 | 8 | 42.1 | 11 | 57.9 | ||||
| Age | 0.126 | 0.722 | 0.145 | 0.704 | ||||||||
| <65 | 14 | 45.2 | 17 | 54.8 | 16 | 51.6 | 15 | 48.4 | ||||
| ≥65 | 28 | 49.1 | 29 | 50.9 | 27 | 47.4 | 30 | 52.6 | ||||
| Pathogenic sites | 6.610 | 0.037 | 7.632 | 0.022 | ||||||||
| Upper | 4 | 80.0 | 1 | 20.0 | 1 | 20.0 | 4 | 80.0 | ||||
| Middle | 6 | 27.3 | 16 | 72.7 | 16 | 72.7 | 6 | 27.3 | ||||
| Lower | 32 | 52.5 | 29 | 47.5 | 26 | 42.6 | 35 | 57.4 | ||||
| Pathological type | 1.711 | 0.191 | 3.366 | 0.067 | ||||||||
| ESCC | 32 | 44.4 | 40 | 55.6 | 39 | 54.2 | 33 | 45.8 | ||||
| Other | 10 | 62.5 | 6 | 37.5 | 4 | 25.0 | 12 | 75.0 | ||||
| TNM stage | 0.964 | 0.618 | 0.336 | 0.845 | ||||||||
| I | 4 | 57.1 | 3 | 42.9 | 3 | 42.9 | 4 | 57.1 | ||||
| II | 10 | 55.6 | 8 | 44.4 | 8 | 44.4 | 10 | 55.6 | ||||
| III | 28 | 44.4 | 35 | 55.6 | 32 | 50.8 | 31 | 49.2 | ||||
| Postoperative metastasis | 0.877 | 0.349 | 1.720 | 0.190 | ||||||||
| Yes | 17 | 44.7 | 21 | 55.3 | 21 | 55.3 | 17 | 44.7 | ||||
| No | 11 | 57.9 | 8 | 42.1 | 7 | 36.8 | 12 | 63.2 | ||||
Prognostic factors according to the univariate analysis
| Factor | Case | OS rate (%) |
| ||
|---|---|---|---|---|---|
| 1 year | 3 years | 5 years | |||
| Sex | 0.323 | ||||
| Male | 69 | 79.7 | 56.5 | 44.9 | |
| Female | 19 | 89.5 | 63.2 | 57.9 | |
| Age | 0.295 | ||||
| <65 | 31 | 80.6 | 58.1 | 48.4 | |
| ≥65 | 57 | 82.5 | 59.6 | 54.4 | |
| Pathogenic sites | 0.034 | ||||
| Upper | 5 | 80.0 | 60.0 | 60.0 | |
| Middle | 22 | 90.9 | 72.7 | 72.7 | |
| Lower | 61 | 78.7 | 54.1 | 44.3 | |
| Pathological type | 0.837 | ||||
| ESCC | 72 | 79.2 | 50.0 | 47.2 | |
| Other | 16 | 81.3 | 56.3 | 50.0 | |
| TNM stage | 0.013 | ||||
| I | 7 | 100.0 | 100.0 | 85.7 | |
| II | 18 | 94.4 | 77.8 | 66.7 | |
| III | 63 | 76.2 | 49.2 | 44.4 | |
| Postoperative metastasis | 0.143 | ||||
| Yes | 38 | 76.3 | 57.9 | 50.0 | |
| No | 19 | 89.5 | 73.7 | 63.2 | |
| miR-21 | 0.039 | ||||
| High | 43 | 69.8 | 51.2 | 44.2 | |
| Low | 45 | 93.3 | 66.7 | 60.0 | |
| miR-375 | 0.022 | ||||
| High | 43 | 95.3 | 67.4 | 60.5 | |
| Low | 45 | 68.9 | 51.1 | 44.4 | |
Fig. 2a Overall survival in EC patients with high and low miR-21 expression. b Overall survival in EC patients with high and low miR-375 expression. c Overall survival in EC patients with both high miR-375 expression and low miR-21 expression
Four-fold table for miR-21 and miR-375
| MiR-21 | MiR-375 | Total | |
|---|---|---|---|
| High | Low | ||
| High | 2 (2.3%) | 40 (45.5%) | 42 |
| Low | 41 (46.6%) | 5 (5.7%) | 46 |
| Total | 43 | 45 | 88 |
Prognostic factors according to the multivariate analysis
| Factor |
| SE |
|
|
|
|---|---|---|---|---|---|
| Pathogenic sites | 0.405 | 0.333 | 1.474 | 1.499 (0.780–2.880) | 0.225 |
| TNM stage | 0.859 | 0.351 | 5.989 | 2.361 (1.187–4.696) | 0.014 |
| miR-21 | 0.764 | 0.314 | 5.910 | 2.146 (1.159–3.972) | 0.015 |
| miR-375 | 0.750 | 0.310 | 5.842 | 0.472 (0.257–0.868) | 0.016 |
Characteristics of included studies with miR-21 expression
| Study | Year | Population | Sample | Histology | N | Stage | PT | Sample collection | Method | Cutoff | HR | Result | Analysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hamano et al. | 2011 | Japanese | Tissue | ESCC | 98 | I–IV | Yes | Formalin-fixed | qRT-PCR | Median value | 2.18 (1.18–4.02) | OS | NT |
| Zhao et al. | 2012 | Chinese | Tissue | ESCC | 178 | I–III | NG | Frozen | qRT-PCR | 3.57-folds | 1.52 (0.90–2.58) | OS | multivariate |
| P Li et al. | 2013 | Chinese | Tissue | ESCC | 76 | I–IV | NG | Frozen | qRT-PCR | 5-folds | 1.45 (0.90–2.32) | DFS | NG |
| B Li et al. | 2015 | Chinese | PB | ESCC | 38 | I–IV | Yes | Frozen | qRT-PCR | Median value | 2.26 (0.88–5.83) | OS | NG |
| Mathe/ANT et al. | 2009 | MCC | Tissue | SCC, ADC | 170 | I–IV | Yes | Frozen | qRT-PCR | Median value | 2.51 (0.62–10.10) | CH | Univariate and multivariate |
| Mathe/CT et al. | 2009 | MCC | Tissue | SCC, ADC | 170 | I–IV | Yes | Frozen | qRT-PCR | Median value | 1.94 (0.48–7.86) | CH | Univariate and multivariate |
| Komatsu et al. | 2012 | Japanese | PB | ESCC | 50 | I–IV | NG | Frozen | qRT-PCR | 0.2227 amol/uL | 2.41 (0.68–8.53) | OS | multivariate |
| Xiang et al. | 2014 | Chinese | Tissue | ESCC | 72 | I–IV | No | Frozen | qRT-PCR | Median value | 2.70 (1.25–5.82) | OS | NG |
Characteristics of included studies with miR-375 expression
| Study | Year | Population | Sample | Histology | N | Stage | PT | Sample collection | Method | Cutoff | HR | Result | Analysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C Wu et al. | 2013 | Chinese | Tissue | ESCC | 20 | I–IV | No | Frozen | qRT-PCR | 2.71-folds | 0.61 (0.40–0.91) | OS | NT |
| Kong et al. | 2011 | Japanese | Tissue | ESCC | 60 | I–IV | NG | Frozen | qRT-PCR | 5.38-folds | 0.46 (0.24–0.86) | OS | NT |
| Mathe/ANT et al. | 2009 | MCC | Tissue | SCC,ADC | 170 | I–IV | Yes | Frozen | qRT-PCR | Median value | 0.64 (0.17–2.40) | CH | Univariate and multivariate |
| Mathe/CT et al. | 2009 | MCC | Tissue | SCC,ADC | 170 | I–IV | Yes | Frozen | qRT-PCR | Median value | 0.33 (0.08–1.32) | CH | Univariate and multivariate |
| B Li et al. | 2015 | Chinese | Tissue | ESCC | 38 | I–IV | No | Formalin-fixed | qRT-PCR | Median value | 0.73 (0.29–1.82) | OS | NG |
| J Li et al. | 2013 | Chinese | Tissue | ESCC | 300 | I–IV | No | Formalin-fixed | qRT-PCR | Normalized against endogenous 18 s | 0.55 (0.34–0.88) | OS | NG |
Fig. 3a Forest plots evaluating the association between miR-21 expression and prognosis in ES. b Forest plots evaluating the association between miR-375 expression and prognosis in ES